UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Journal of clinical oncology, 2018-08, Vol.36 (22), p.2267-2280

2018

Volltextzugriff (PDF)

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma

Journal of clinical oncology, 2018-10, Vol.36 (28), p.2863-2871

2018

Volltextzugriff (PDF)

Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance

Journal of clinical oncology, 2021-09, Vol.39 (25), p.JCO2002636-2790

2021

Volltextzugriff (PDF)

Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials

Journal of clinical oncology, 2022-05, Vol.40 (15), p.1623-1634

2022

Volltextzugriff (PDF)

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5515-5515

2023

Volltextzugriff (PDF)

Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: A systematic scoping review and meta-analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3089-3089

2021

Volltextzugriff (PDF)

A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2034-2034

2023

Volltextzugriff (PDF)

Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3125-3125

2023

Volltextzugriff (PDF)

Genomic landscape of malignant peripheral nerve sheath tumor (MPNST)-like melanoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e22072-e22072

2020

Volltextzugriff (PDF)

Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e15038-e15038

2021

Volltextzugriff (PDF)

Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3052-3052

2018

Volltextzugriff (PDF)

Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.8564-8564

2018

Volltextzugriff (PDF)

Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12093-12093

2018

Volltextzugriff (PDF)

Evaluation of homeobox (HOX) gene expression as a prognostic biomarker of time to recurrence (TTR) in high grade serous ovarian cancer (HGSOC) patients treated with adjuvant carboplatin plus paclitaxel (A-C/P)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e17046-e17046

2016

Volltextzugriff (PDF)

A phase 2 trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in subjects with metastatic pancreatic cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.4135-4135

2014

Volltextzugriff (PDF)

A phase II trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in patients with metastatic pancreatic cancer

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.213-213

2014

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(17)

Sprache

Englisch
(17)

Erscheinungsjahr

n.n

Thema

Oncology
(6)
Life Sciences & Biomedicine
(5)
Original Reports
(5)
Science & Technology
(5)
Humans
(4)
Female
(3)
Male
(3)
Adult
(2)
Aged
(2)
Middle Aged
(2)
T-Lymphocytes - Immunology
(2)
T-Lymphocytes - Transplantation
(2)
Adolescent
(1)
Aged, 80 And Over
(1)
Anorexia
(1)
Antigens, Cd19 - Immunology
(1)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(1)
B-Cell Maturation Antigen - Genetics
(1)
B-Cell Maturation Antigen - Immunology
(1)
Cancer And Oncology
(1)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Elektronische Zeitschriftenbibliothek (Open access)
(17)
Journals@Ovid Full Text
(17)
Single Journals
(17)
IngentaConnect Journals
(11)
IngentaConnect Journals
(11)
MEDLINE
(4)

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma

Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance

Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: A systematic scoping review and meta-analysis

A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis

Genomic landscape of malignant peripheral nerve sheath tumor (MPNST)-like melanoma

Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts)

Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions

Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma

Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM)

Evaluation of homeobox (HOX) gene expression as a prognostic biomarker of time to recurrence (TTR) in high grade serous ovarian cancer (HGSOC) patients treated with adjuvant carboplatin plus paclitaxel (A-C/P)

A phase 2 trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in subjects with metastatic pancreatic cancer

A phase II trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in patients with metastatic pancreatic cancer

Aktive Filter

Suchergebnisse filtern